We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+11.43%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$990M
AUM Growth
-$95.1M
Cap. Flow
-$12.4M
Cap. Flow %
-1.25%
Top 10 Hldgs %
70.6%
Holding
53
New
12
Increased
7
Reduced
12
Closed
14

Top Buys

Rank Stock Value
1
KYNB
Kyntra Bio
KYNB
+$58.8M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$42.9M
3
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
+$34.9M
4
BCEL
Atreca, Inc. Class A Common Stock
BCEL
+$26.8M
5
CYCN icon
Cyclerion Therapeutics
CYCN
+$11M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$42.5M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$31.3M
3
ARGX icon
argenx
ARGX
+$31M
4
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$24.9M
5
DNTH icon
Dianthus Therapeutics
DNTH
+$21M

Sector Composition

Rank Sector Weight
1 Healthcare 98.05%
2 Miscellaneous 1.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
51
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-348,900
Closed -$25.6M
MYOK
52
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-478,574
Closed -$24.9M
SNNA
53
DELISTED
Sienna Biopharmaceuticals, Inc.
SNNA
– –
-800,000
Closed -$1.86M
1 2
3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2019 Portfolio in Review

As of Q2 2019, EcoR1 Capital held 53 positions worth $990M, down 8.8% from $1.08B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

EcoR1 Capital's Q2 2019 filing shows 12 new, 7 increased, 12 reduced and 14 closed positions. Its largest new stake was Morphic Holding, Inc. Common Stock: 2,266,804 shares worth $44.9M. The largest sale was Ascendis Pharma A/S, an estimated $42.5M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 85% a quarter earlier, followed by Miscellaneous.

  • EcoR1 Capital's largest Q2 2019 buy was Morphic Holding, Inc. Common Stock: 2,266,804 shares worth $44.9M.
  • EcoR1 Capital added most to Kyntra Bio in Q2 2019, an estimated $58.8M increase.
  • EcoR1 Capital's biggest Q2 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $31.3M.
  • EcoR1 Capital fully exited Ascendis Pharma A/S in Q2 2019, selling an estimated $42.5M.
  • EcoR1 Capital's ten largest holdings make up 71% of its $990M portfolio in Q2 2019.
  • EcoR1 Capital opened 12 new positions and closed 14 in Q2 2019.
  • EcoR1 Capital's portfolio value fell 8.8% quarter-over-quarter to $990M.

Based on EcoR1 Capital's 13F filing for Q2 2019, filed 14 Aug 2019.